{"brief_title": "Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.", "brief_summary": "This drug is being developed to treat a type of brain cancer, glioma. This study was designed to determine a safe and well tolerated dose. Patients must have had prior treatment for their glioma and be eligible for removal of their recurring tumor.", "detailed_description": "This is an open label single-dose study to be conducted in 18 evaluable patients with recurrent high-grade glioma. Patient will undergone debulking surgery and ventricular access device placement into the tumor cavity for administration of 131I-TM-601. High-grade glioma includes glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligo-astrocytoma and gliosarcoma. The amount of 131I will remain constant. Three doses of TM-601 will be administered using a dose escalating scheme.", "condition": ["Glioma", "Brain Neoplasm"], "intervention_type": ["Drug"], "intervention_name": ["131I-TM-601"], "criteria": "- Patient must have given informed consent - Patient must have histologically confirmed supratentorial malignant glioma - Patients must have recovered from toxicity of prior therapy - Patients must be eligble for resection of the recurrent tumor", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Clinical trial, phase I/II", "mesh_term": ["Glioma", "Brain Neoplasms"], "id": "NCT00040573"}